{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:57:48Z","timestamp":1792184268481,"version":"4.4.0"},"reference-count":146,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100006701","name":"Deanship of Scientific Research at Umm Al-Qura University","doi-asserted-by":"publisher","award":["22UQU4350477DSR08"],"award-info":[{"award-number":["22UQU4350477DSR08"]}],"id":[{"id":"10.13039\/501100006701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Viruses are still the most prevalent infectious pathogens on a worldwide scale, with many\nof them causing life-threatening illnesses in humans. Influenza viruses, because of their significant\nmorbidity and mortality, continue to pose a major threat to human health. According to WHO statistics,\nseasonal influenza virus epidemics are predicted to cause over 2 million severe illness cases with\nhigh death rates yearly. The whole world has been suffering from the COVID-19 epidemic for two\nyears and is still suffering so far, and the deaths from this virus have exceeded three million cases.\nBecause the great majority of viral infections do not have a specific medication or vaccination, discovering\nnovel medicines remains a vital task. This review covers reports in the patent literature from\n1980 to the end of 2021 on the antiviral activities of pyrimidine moieties. The patent database,\nSciFinder, was used to locate patent applications. A large variety of pyrimidine molecules have been\nproduced and tested for antiviral activity over the last decade. These molecules were reported to inhibit\na wide range of viruses, including influenza virus, respiratory syncytial virus, rhinovirus, dengue\nvirus, herpes virus, hepatitis B and C, and human immunodeficiency virus. The cytotoxicity of the\ndeveloped pyrimidine derivatives was tested in almost all reported studies and the selectivity index\nwas calculated to show the selectivity and safety of such molecules. From the remarkable activity of\npyrimidine compounds as antivirals for several dangerous viruses, we expect that these derivatives\nwill be used as potent drugs in the very near future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1389557523666221220142911","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T02:36:31Z","timestamp":1671676591000},"page":"821-851","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Antiviral Activity of Pyrimidine Containing Compounds: Patent Review"],"prefix":"10.2174","volume":"23","author":[{"given":"Thoraya A.","family":"Farghaly","sequence":"first","affiliation":[{"name":"Department of Chemistry, Faculty of Applied Science, Umm Al-Qura University, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa F.","family":"Harras","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani M.R.","family":"Alsaedi","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Collage of Science, Taif University, P. O. Box 11099, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima A.","family":"Thakir","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Al-Qunfudah University College, Umm Al-Qura University, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda K.","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina F.","family":"Katowah","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Applied Science, Umm Al-Qura University, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1128\/AAC.00282-16","volume":"60","author":"Chung D.H.","year":"2016","unstructured":"Chung D.H.; Golden J.E.; Adcock R.S.; Schroeder C.E.; Chu Y.K.; Sotsky J.B.; Cramer D.E.; Chilton P.M.; Song C.; Anantpadma M.; Davey R.A.; Prodhan A.I.; Yin X.; Zhang X.; Discovery of a broad-spectrum antiviral compound that inhibits pyrimidine biosynthesis and establishes a type 1 interferon-independent antiviral state. Antimicrob Agents Chemother 2016,60(8),4552-4562","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"105076","DOI":"10.1016\/j.bioorg.2021.105076","volume":"114","author":"Mermer A.","year":"2021","unstructured":"Mermer A.; Keles T.; Sirin Y.; Recent studies of nitrogen containing heterocyclic compounds as novel antiviral agents: A review. Bioorg Chem 2021,114,105076","journal-title":"Bioorg Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","volume":"10","author":"Wu C.","year":"2020","unstructured":"Wu C.; Liu Y.; Yang Y.; Zhang P.; Zhong W.; Wang Y.; Wang Q.; Xu Y.; Li M.; Li X.; Zheng M.; Chen L.; Li H.; Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020,10(5),766-788","journal-title":"Acta Pharm Sin B"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.aivir.2018.01.001","author":"Corman V.M.","year":"2018","unstructured":"Corman V.M.; Hosts and sources of endemic human coronaviruses. Advances in virus research 2018,163-188","journal-title":"Advances in virus research"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.coviro.2013.03.001","volume":"3","author":"Debing Y.","year":"2013","unstructured":"Debing Y.; Jochmans D.; Neyts J.; Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol 2013,3(2),217-224","journal-title":"Curr Opin Virol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"113161","DOI":"10.1016\/j.ejmech.2021.113161","volume":"213","author":"Xiao M.","year":"2021","unstructured":"Xiao M.; Xu L.; Lin D.; Lian W.; Cui M.; Zhang M.; Yan X.; Li S.; Zhao J.; Ye J.; Liu A.; Hu A.; Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors. Eur J Med Chem 2021,213,113161","journal-title":"Eur J Med Chem"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/138945010790711932","volume":"11","author":"Mitrasinovic P.","year":"2010","unstructured":"Mitrasinovic P.; Advances in the structure-based design of the influenza A neuraminidase inhibitors. Curr Drug Targets 2010,11(3),315-326","journal-title":"Curr Drug Targets"},{"key":"ref=8","first-page":"551","volume":"65","author":"Schwerdtfeger S.M.","year":"2010","unstructured":"Schwerdtfeger S.M.; Melzig M.F.; Sialidases in biological systems. Pharmazie 2010,65(8),551-561","journal-title":"Pharmazie"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"16761","DOI":"10.1074\/jbc.RA118.004862","volume":"293","author":"Cox R.M.","year":"2018","unstructured":"Cox R.M.; Toots M.; Yoon J.J.; Sourimant J.; Ludeke B.; Fearns R.; Bourque E.; Patti J.; Lee E.; Vernachio J.; Plemper R.K.; Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex. J Biol Chem 2018,293(43),16761-16777","journal-title":"J Biol Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1021\/acsmedchemlett.7b00418","volume":"9","author":"Shi W.","year":"2018","unstructured":"Shi W.; Jiang Z.; He H.; Xiao F.; Lin F.; Sun Y.; Hou L.; Shen L.; Han L.; Zeng M.; Lai K.; Gu Z.; Chen X.; Zhao T.; Guo L.; Yang C.; Li J.; Chen S.; Discovery of 3,3\u2032-Spiro[Azetidine]-2-oxo-indoline derivatives as fusion inhibitors for treatment of RSV infection. ACS Med Chem Lett 2018,9(2),94-97","journal-title":"ACS Med Chem Lett"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"13293","DOI":"10.3748\/wjg.v20.i37.13293","volume":"20","author":"You C.R.","year":"2014","unstructured":"You C.R.; Lee S.W.; Jang J.W.; Yoon S.K.; Update on hepatitis B virus infection. World J Gastroenterol 2014,20(37),13293-13305","journal-title":"World J Gastroenterol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"Gower E.","year":"2014","unstructured":"Gower E.; Estes C.; Blach S.; Razavi-Shearer K.; Razavi H.; Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014,61(S1),S45-S57","journal-title":"J Hepatol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/AAC.01216-09","volume":"54","author":"Powdrill M.H.","year":"2010","unstructured":"Powdrill M.H.; Deval J.; Narjes F.; De Francesco R.; G\u00f6tte M.; Mechanism of hepatitis C virus RNA polymerase inhibition with dihydroxypyrimidines. Antimicrob Agents Chemother 2010,54(3),977-983","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1021\/jm051064t","volume":"49","author":"Koch U.","year":"2006","unstructured":"Koch U.; Attenni B.; Malancona S.; Colarusso S.; Conte I.; Di Filippo M.; Harper S.; Pacini B.; Giomini C.; Thomas S.; Incitti I.; Tomei L.; De Francesco R.; Altamura S.; Matassa V.G.; Narjes F.; 2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis. J Med Chem 2006,49(5),1693-1705","journal-title":"J Med Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1021\/jm0342109","volume":"47","author":"Summa V.","year":"2004","unstructured":"Summa V.; Petrocchi A.; Pace P.; Matassa V.G.; De Francesco R.; Altamura S.; Tomei L.; Koch U.; Neuner P.; Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J Med Chem 2004,47(1),14-17","journal-title":"J Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"111864","DOI":"10.1016\/j.ejmech.2019.111864","volume":"186","author":"Xiao T.","year":"2020","unstructured":"Xiao T.; Tang J.F.; Meng G.; Pannecouque C.; Zhu Y.Y.; Liu G.Y.; Xu Z.Q.; Wu F.S.; Gu S.X.; Chen F.E.; Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. Eur J Med Chem 2020,186,111864","journal-title":"Eur J Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1021\/acs.jmedchem.9b02149","volume":"63","author":"Curreli F.","year":"2020","unstructured":"Curreli F.; Ahmed S.; Benedict Victor S.M.; Iusupov I.R.; Belov D.S.; Markov P.O.; Kurkin A.V.; Altieri A.; Debnath A.K.; Preclinical optimization of gp120 entry-antagonists as anti- HIV-1 agents with improved cytotoxicity and ADME properties through rational design, synthesis, and antiviral evaluation. J Med Chem 2020,63(4),1724-1749","journal-title":"J Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1021\/acsmedchemlett.9b00619","volume":"11","author":"Cannalire R.","year":"2020","unstructured":"Cannalire R.; Ki Chan K.W.; Burali M.S.; Gwee C.P.; Wang S.; Astolfi A.; Massari S.; Sabatini S.; Tabarrini O.; Mastrangelo E.; Barreca M.L.; Cecchetti V.; Vasudevan S.G.; Manfroni G.; Pyridobenzothiazolones exert potent anti-dengue activity by hampering multiple functions of NS5 polymerase. ACS Med Chem Lett 2020,11(5),773-782","journal-title":"ACS Med Chem Lett"},{"key":"ref=19","first-page":"e62467\/1","volume":"11","author":"Yasmin F.","year":"2018","unstructured":"Yasmin F.; Yaqub T.; Khan I.; Shahzad W.; Abu Saeed H.; Tahir Z.; Mukhtar N.; Umar S.; Antiviral activity of thiazolide derivatives against dengue virus in Huh-7 cell line J Microbiol 2018,11(2),e62467\/1-e62467\/6","journal-title":"J Microbiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1099\/vir.0.82714-0","volume":"88","author":"Arankalle V.A.","year":"2007","unstructured":"Arankalle V.A.; Shrivastava S.; Cherian S.; Gunjikar R.S.; Walimbe A.M.; Jadhav S.M.; Sudeep A.B.; Mishra A.C.; Genetic divergence of Chikungunya viruses in India (1963\u20132006) with special reference to the 2005\u20132006 explosive epidemic. J Gen Virol 2007,88(7),1967-1976","journal-title":"J Gen Virol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.1021\/acsomega.0c06191","volume":"6","author":"Ivanova L.","year":"2021","unstructured":"Ivanova L.; Rausalu K.; \u017dusinaite E.; Tammiku-Taul J.; Merits A.; Karelson M.; 1,3-Thiazolbenzamide derivatives as Chikungunya Virus nsP2 protease inhibitors. ACS Omega 2021,6(8),5786-5794","journal-title":"ACS Omega"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fmicb.2020.00139","volume":"11","author":"\u00c1lvarez D.M.","year":"2020","unstructured":"\u00c1lvarez D.M.; Castillo E.; Duarte L.F.; Arriagada J.; Corrales N.; Far\u00edas M.A.; Henr\u00edquez A.; Agurto-Mu\u00f1oz C.; Gonz\u00e1lez P.A.; Current antivirals and novel botanical molecules interfering with Herpes simplex virus infection. Front Microbiol 2020,11,139","journal-title":"Front Microbiol"},{"key":"ref=23","first-page":"204","volume":"16","author":"Lolis M.S.","year":"2008","unstructured":"Lolis M.S.; Gonz\u00e1lez L.; Cohen P.J.; Schwartz R.A.; Drugresistant Herpes simplex virus in HIV infected patients Acta Dermatovenerol Croat 2008,16(4),204-208","journal-title":"Acta Dermatovenerol Croat"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.bmcl.2007.11.120","volume":"18","author":"Gudmundsson K.S.","year":"2008","unstructured":"Gudmundsson K.S.; Johns B.A.; Allen S.H.; Pyrazolopyridines with potent activity against herpesviruses: Effects of C5 substituents on antiviral activity. Bioorg Med Chem Lett 2008,18(3),1157-1161","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.ejmech.2009.03.038","volume":"44","author":"Sabbagh E.","year":"2009","unstructured":"Sabbagh E.; Baraka M.M.; Ibrahim S.M.; Pannecouque C.; Andrei G.; Snoeck R.; Balzarini J.; Rashad A.; Synthesis and antiviral activity of new pyrazole and thiazole derivatives Eur J Med Chem 2009,44,3746-3753","journal-title":"Eur J Med Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1080\/13102818.2019.1680318","volume":"33","author":"Petrov N.","year":"2019","unstructured":"Petrov N.; Stoyanova M.; Galabov A.; Inhibition of Coxsackievirus B3 cardiotropic strain Woodruff replication by silencing essential viral genes. Biotechnol Biotechnol Equip 2019,33(1),1582-1589","journal-title":"Biotechnol Biotechnol Equip"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.3390\/v13091784","volume":"13","author":"Real-Hohn A.","year":"2021","unstructured":"Real-Hohn A.; Blaas D.; Rhinovirus inhibitors: Including a new target, the viral RNA. Viruses 2021,13(9),1784","journal-title":"Viruses"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","volume":"17","author":"Kaufmann S.H.E.","year":"2018","unstructured":"Kaufmann S.H.E.; Dorhoi A.; Hotchkiss R.S.; Bartenschlager R.; Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov 2018,17(1),35-56","journal-title":"Nat Rev Drug Discov"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","volume":"16","author":"Zumla A.","year":"2016","unstructured":"Zumla A.; Rao M.; Wallis R.S.; Kaufmann S.H.E.; Rustomjee R.; Mwaba P.; Vilaplana C.; Yeboah-Manu D.; Chakaya J.; Ippolito G.; Azhar E.; Hoelscher M.; Maeurer M.; Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis 2016,16(4),e47-e63","journal-title":"Lancet Infect Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ejphar.2017.05.038","volume":"809","author":"van de Wakker S.I.","year":"2017","unstructured":"van de Wakker S.I.; Fischer M.J.E.; Oosting R.S.; New drug-strategies to tackle viral-host interactions for the treatment of influenza virus infections. Eur J Pharmacol 2017,809,178-190","journal-title":"Eur J Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"10968","DOI":"10.1073\/pnas.1901214116","volume":"116","author":"Ashraf U.","year":"2019","unstructured":"Ashraf U.; Tengo L.; Le Corre L.; Fournier G.; Busca P.; McCarthy A.A.; Rameix-Welti M.A.; Gravier-Pelletier C.; Ruigrok R.W.H.; Jacob Y.; Vidalain P.O.; Pietrancosta N.; Cr\u00e9pin T.; Naffakh N.; Destabilization of the human RED\u2013SMU1 splicing complex as a basis for host-directed antiinfluenza strategy. Proc Natl Acad Sci 2019,116(22),10968-10977","journal-title":"Proc Natl Acad Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.3390\/v13122379","volume":"13","author":"Ezeonwumelu I.J.","year":"2021","unstructured":"Ezeonwumelu I.J.; Garcia-Vidal E.; Ballana E.; JAK-STAT Pathway: A novel target to tackle viral infections. Viruses 2021,13(12),2379","journal-title":"Viruses"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1159\/000508247","volume":"181","author":"Seif F.","year":"2020","unstructured":"Seif F.; Aazami H.; Khoshmirsafa M.; Kamali M.; Mohsenzadegan M.; Pornour M.; Mansouri D.; JAK inhibition as a new treatment strategy for patients with COVID-19. Int Arch Allergy Immunol 2020,181(6),467-475","journal-title":"Int Arch Allergy Immunol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11481-018-09829-8","volume":"14","author":"Saminathan P.","year":"2019","unstructured":"Saminathan P.; Kevadiya B.D.; Marker D.F.; Gendelman H.E.; Gorantla S.; Gelbard H.A.; Broad spectrum mixed lineage kinase type 3 inhibition and HIV-1 persistence in macrophages. J Neuroimmune Pharmacol 2019,14(1),44-51","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fnins.2020.00193","volume":"14","author":"Ahmadi Rastegar D.","year":"2020","unstructured":"Ahmadi Rastegar D.; Dzamko N.; Leucine rich repeat kinase 2 and innate immunity. Front Neurosci 2020,14,193","journal-title":"Front Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11904-011-0106-4","volume":"9","author":"Porichis F.","year":"2012","unstructured":"Porichis F.; Kaufmann D.E.; Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV\/AIDS Rep 2012,9(1),81-90","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3389\/fcimb.2019.00207","volume":"9","author":"Sch\u00f6nrich G.","year":"2019","unstructured":"Sch\u00f6nrich G.; Raftery M.J.; The PD-1\/PD-L1 axis and virus infections: A delicate balance. Front Cell Infect Microbiol 2019,9,207","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1016\/j.bbagen.2013.02.008","volume":"1830","author":"Cragg G.M.","year":"2013","unstructured":"Cragg G.M.; Newman D.J.; Natural products: A continuing source of novel drug leads. Biochim Biophys Acta, Gen Subj 2013,1830(6),3670-3695","journal-title":"Biochim Biophys Acta, Gen Subj"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/13543776.2022.2067477","volume":"32","author":"Farghaly T.A.","year":"2022","unstructured":"Farghaly T.A.; Alsaedi A.M.R.; Alenazi N.A.; Harras M.F.; Anti-viral activity of thiazole derivatives: an updated patent review. Expert Opin Ther Pat 2022,32(7),791-815","journal-title":"Expert Opin Ther Pat"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cbdv.200490173","volume":"2","author":"Lagoja I.M.","year":"2005","unstructured":"Lagoja I.M.; Pyrimidine as constituent of natural biologically active compounds. Chem Biodivers 2005,2(1),1-50","journal-title":"Chem Biodivers"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.tetlet.2007.11.009","volume":"49","author":"Choudhury A.","year":"2008","unstructured":"Choudhury A.; Chen H.; Nilsen C.N.; Sorgi K.L.; A chemoselective aniline\u2013chloropyrimidine coupling in a competing electrophilic environment. Tetrahedron Lett 2008,49(1),102-105","journal-title":"Tetrahedron Lett"},{"key":"ref=42","first-page":"57","volume":"3","author":"Brown D.J.","year":"1984","unstructured":"Brown D.J.; Pyrimidines and their benzo derivatives Compre Heterocyclic Chem 1984,3,57-155","journal-title":"Compre Heterocyclic Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.fjps.2015.12.001","volume":"2","author":"Aziz M.A.","year":"2016","unstructured":"Aziz M.A.; Serya R.A.T.; Lasheen D.S.; Abouzid K.A.M.; Furo[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents. Fut J Pharm Sci 2016,2(1),1-8","journal-title":"Fut J Pharm Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1016\/j.ejmech.2009.06.024","volume":"44","author":"Padmaja A.","year":"2009","unstructured":"Padmaja A.; Payani T.; Reddy G.D.; Padmavathi V.; Synthesis, antimicrobial and antioxidant activities of substituted pyrazoles, isoxazoles, pyrimidine and thioxopyrimidine derivatives. Eur J Med Chem 2009,44(11),4557-4566","journal-title":"Eur J Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1021\/jm051065l","volume":"49","author":"Goodacre S.C.","year":"2006","unstructured":"Goodacre S.C.; Street L.J.; Hallett D.J.; Crawforth J.M.; Kelly S.; Owens A.P.; Blackaby W.P.; Lewis R.T.; Stanley J.; Smith A.J.; Ferris P.; Sohal B.; Cook S.M.; Pike A.; Brown N.; Wafford K.A.; Marshall G.; Castro J.L.; Atack J.R.; Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)\u03b12\/\u03b13 binding site agonists for the treatment of anxiety disorders. J Med Chem 2006,49(1),35-38","journal-title":"J Med Chem"},{"key":"ref=46","first-page":"171","volume":"8","author":"Dansena H.","year":"2015","unstructured":"Dansena H.; Dhongade H.; Chandrakar K.; Pharmacological potentials of pyrimidine derivative: a review Asian J Pharm Clin Res 2015,8(4),171-177","journal-title":"Asian J Pharm Clin Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/00397911.2016.1165254","volume":"46","author":"Mohana Roopan S.","year":"2016","unstructured":"Mohana Roopan S.; Sompalle R.; Synthetic chemistry of pyrimidines and fused pyrimidines: A review. Synth Commun 2016,46(8),645-672","journal-title":"Synth Commun"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0959-6380(07)80009-2","volume":"18","author":"Gordon W.","year":"2007","unstructured":"Gordon W.; John A.; A critical review of the 2005 literature preceded by two chapters on current heterocyclic topics Prog Heterocyclic Chem 2007,18,126-149","journal-title":"Prog Heterocyclic Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"113218","DOI":"10.1016\/j.ejmech.2021.113218","volume":"214","author":"Wang S.","year":"2021","unstructured":"Wang S.; Yuan X.H.; Wang S.Q.; Zhao W.; Chen X.B.; Yu B.; FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. Eur J Med Chem 2021,214,113218","journal-title":"Eur J Med Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.dcmed.2021.06.004","volume":"4","author":"Khan S.","year":"2021","unstructured":"Khan S.; Kale M.; Siddiqui F.; Nema N.; Novel pyrimidine-benzimidazole hybrids with antibacterial and antifungal properties and potential inhibition of SARS-CoV-2 main protease and spike glycoprotein. Digi Chinese Med 2021,4(2),102-119","journal-title":"Digi Chinese Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/07328303.2018.1543430","volume":"38","author":"Elgemeie G.H.","year":"2019","unstructured":"Elgemeie G.H.; Mohamed R.A.; Microwave chemistry: Synthesis of purine and pyrimidine nucleosides using microwave radiation. J Carbohydr Chem 2019,38(1),20-66","journal-title":"J Carbohydr Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1039\/B816215H","volume":"27","author":"Winn M.","year":"2010","unstructured":"Winn M.; Goss R.J.M.; Kimura K.; Bugg T.D.H.; Antimicrobial nucleoside antibiotics targeting cell wall assembly: Recent advances in structure\u2013function studies and nucleoside biosynthesis. Nat Prod Rep 2010,27(2),279-304","journal-title":"Nat Prod Rep"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1039\/c3cs00003f","volume":"42","author":"Boutureira O.","year":"2013","unstructured":"Boutureira O.; Matheu M.I.; D\u00edaz Y.; Castill\u00f3n S.; Advances in the enantioselective synthesis of carbocyclic nucleosides. Chem Soc Rev 2013,42(12),5056-5072","journal-title":"Chem Soc Rev"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1021\/bc5003554","volume":"25","author":"Dziuba D.","year":"2014","unstructured":"Dziuba D.; Pohl R.; Hocek M.; Bodipy-labeled nucleoside triphosphates for polymerase synthesis of fluorescent DNA. Bioconjug Chem 2014,25(11),1984-1995","journal-title":"Bioconjug Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"De Clercq E.","year":"2016","unstructured":"De Clercq E.; Li G.; Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 2016,29(3),695-747","journal-title":"Clin Microbiol Rev"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"14379","DOI":"10.1021\/acs.chemrev.6b00209","volume":"116","author":"Shelton J.","year":"2016","unstructured":"Shelton J.; Lu X.; Hollenbaugh J.A.; Cho J.H.; Amblard F.; Schinazi R.F.; Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, KL. Chem Rev 2016,116(23),14379-14455","journal-title":"Chem Rev"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejmech.2012.04.001","volume":"53","author":"Sari O.","year":"2012","unstructured":"Sari O.; Roy V.; Balzarini J.; Snoeck R.; Andrei G.; Agrofoglio L.A.; Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2\u2032-deoxyuridines. Eur J Med Chem 2012,53,220-228","journal-title":"Eur J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","volume":"68","author":"Clercq E.D.","year":"2004","unstructured":"Clercq E.D.; Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 2004,68(12),2301-2315","journal-title":"Biochem Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1021\/jm0701472","volume":"50","author":"Cristofoli W.A.","year":"2007","unstructured":"Cristofoli W.A.; Wiebe L.I.; De Clercq E.; Andrei G.; Snoeck R.; Balzarini J.; Knaus E.E.; 5-alkynyl analogs of arabinouridine and 2\u2032-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells. J Med Chem 2007,50(12),2851-2857","journal-title":"J Med Chem"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1039\/b516804j","volume":"4","author":"Skorobogatyi M.V.","year":"2006","unstructured":"Skorobogatyi M.V.; 5-Arylethynyl-2\u2032-deoxyuridines, compounds active against HSV-1 Organic Biomolecular Chem 2006,4(6),1091-1096","journal-title":"Organic Biomolecular Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1039\/C4CC09844G","volume":"51","author":"Niu H.Y.","year":"2015","unstructured":"Niu H.Y.; Du C.; Xie M.S.; Wang Y.; Zhang Q.; Qu G.R.; Guo H.M.; Diversity-oriented synthesis of acyclic nucleosides via ring-opening of vinyl cyclopropanes with purines. Chem Commun 2015,51(16),3328-3331","journal-title":"Chem Commun"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1016\/j.bmc.2017.06.046","volume":"25","year":"2017","unstructured":"Kre\u010dmerov\u00e1, M.; Dra\u010d\u00ednsk\u00fd, M.; Snoeck, R.; Balzarini, J.; Pomeisl, K.; Andrei, G. New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity. Bioorg Med Chem 2017,25(17),4637-4648","journal-title":"Bioorg Med Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2191-2858-2-34","volume":"2","author":"Bano T.","year":"2012","unstructured":"Bano T.; Kumar N.; Dudhe R.; Free radical scavenging properties of pyrimidine derivatives. Org Med Chem Lett 2012,2(1),34","journal-title":"Org Med Chem Lett"},{"key":"ref=64","author":"Xu A.","year":"2021","unstructured":"Xu A.; Zhou N.; Zhang X.; Preparation and antiviral activity of pyrazolopyridinyl pyrimidines Faming Zhuanli Shenqing. 2021"},{"key":"ref=65","author":"Naffakh N.","year":"2020","unstructured":"Naffakh N.; Crepin T.; Vidalain P.-O.; Pietrancosta N.; Le Corre L.; Busca P.; Ashraf U.; Corio A.; Gravier-Pelletier C.; Antiviral and anti-cancer activity of pyrido[2,3-d]pyrimidine and oxadiazole compounds. 2020"},{"key":"ref=66","author":"Naffakh N.","year":"2020","unstructured":"Naffakh N.; Crepin T.; Vidalain P-O.; Pietrancosta N.; Le Corre L.; Busca P.; Ashraf U.; Corio A.; Gravier-Pelletier C.; Anti-viral and anti-cancer activity of pyrido[2,3-d]pyrimidine and oxadiazole compounds. 2020"},{"key":"ref=67","author":"Kiselev O. I.","year":"2016","unstructured":"Kiselev O. I.; Chupakhin O. N.; Charushin V. N.; Rusinov V. L.; Deeva E. G.; Ulomskii E. N.; Injection or infusion solution of Larginine salt of 5-methyl-6-nitro-1,2,4-triazolo[1,5-a]pyrimidin-7- one monohydrate for therapy of influenza and other viral infections.  2016"},{"key":"ref=68","author":"Chupakhin O.N.","year":"2008","unstructured":"Chupakhin O.N.; Rusinov V.L.; Ulomskii E.N.; Charushin V.N.; Petrov A.Yu.; Kiselev O.I.; Sodium salt 5-methyl-6-nitro- 1,2,4-triazole[1,5-a]pyrimidine-7-one dehydrate 2008"},{"key":"ref=69","author":"Hu Y.","year":"2007","unstructured":"Hu Y.; Lou L.; Cheng G.; Xu Y.; Xie F.; Tang W.; Li J.; Method for preparation of new type of small molecule pyrimidine derivatives with antitumor and antivirus activities. 2007"},{"key":"ref=70","author":"Li A.","year":"2021","unstructured":"Li A.; Jadaf P. K.; Yao Y.; Chen Y.; Cao G.; Preparation of pyrimidinamine derivatives as Jak kinase inhibitor and used for preventing and\/or treating diseases or disorders related to Jak kinase activity or expression, Faming Zhuanli Shenqing. 2021"},{"key":"ref=71","author":"Yao Y.","year":"2021","unstructured":"Yao Y.; Li A.; Jadaf P. K.; Cao G.; Preparation of (pyrimidinyl) thiadiazabicyclo[3.2.1]octane derivatives as JAK kinase inhibitor and used for preventing and\/or treating diseases or disorders related to JAK kinase activity or expression. 2021"},{"key":"ref=72","author":"Kim P. H.","year":"2021","unstructured":"Kim P. H.; Kim S. H.; Novel pyrimidine derivative and use thereof. 2021"},{"key":"ref=73","author":"Liu Q.","year":"2021","unstructured":"Liu Q.; Khosla C.; Gupta A.; Enhancing the antiviral efficacy of RNA virus inhibition by combination with modulators of pyrimidine metabolism. 2021"},{"key":"ref=74","author":"Moesslacher J.","year":"2020","unstructured":"Moesslacher J.; Battisti V.; Langer T.; Urban E.; Puerstinger G.; Abdelnabi R.; Delang L.; Jochmans D.; Leyssen P.; Marchand A.; Preparation of substituted pyrimidinylpiperazines as antiviral compounds. 2020"},{"key":"ref=75","author":"Li Y.","year":"2019","unstructured":"Li Y.; Li Z.; Cen S.; Peng Z.; Li J.; Wang Y.; Quan Y.; Zhou R.; Aroyl piperazine compounds with inhibitory activity to hepatitis C virus as well as Zika virus replication, preparation method and application thereof in antivirus. 2019"},{"key":"ref=76","author":"Kim Jong U.","year":"2008","unstructured":"Kim Jong U.; Lee Sang Uk; Lee Geun Hyeong; Han Jae Jin; Park Sang Jin; Park Eul Yong; Shin Jung Cheol; Lim, Jong Hwan 2-(Methylthio)pyrimidine derivatives, their preparation method, and antiviral composition containing them, Repub. 2008"},{"key":"ref=77","author":"Herdewijn P.A.M.M.","year":"2008","unstructured":"Herdewijn P.A.M.M.; De Jonghe S.C.A.; Watkins W.J.; Chong L.S.; Zhang J.; Pyrido[3,2-d]pyrimidines as antiviral agents and their pharmaceutical compositions and use in the treatment of viral infections. 2008"},{"key":"ref=78","author":"Venkateshappa C.","year":"2019","unstructured":"Venkateshappa C.; Duraiswamy A.J.; Putta R.K.V.P.; Pyrimidine derivatives as inhibitors of PD1\/PD-L1 activation and their preparation.  2019"},{"key":"ref=79","author":"Pellacini F.","year":"1998","unstructured":"Pellacini F.; Ungheri D.; Schioppacassi G.; Kraus J-L.; Camplo M.; Mourier N.; Chermann J-C.; Preparation of pyrimidinone-1,3-oxathiolane nucleosides as antiviral agents. 1998"},{"key":"ref=80","author":"Son J. C.","year":"1997","unstructured":"Son J. C.; Lee I. Y.; Kim H. S.; Kim J. C.; Cho E. H.; Chung S. G.; Kim J. Y.; Lee S. H.; Kwon H. S.; Lee J. W.; Preparation of 2,4-pyrimidinedione acyclic nucleosides as virucides for AIDS treatment. 1997"},{"key":"ref=81","author":"Cho E. H.","year":"1997","unstructured":"Cho E. H.; Chung S. G.; Kim J. Y.; Kwon H. S.; Lee S. H.; Lee J. E.; Joo J. H.; Kim B. C.; Kang D. W.; Preparation of substituted pyrimidinedione homo-carbocyclic nucleosides as virucides. 1997"},{"key":"ref=82","author":"D\u2019cruz O.","year":"2002","unstructured":"D\u2019cruz O.; Uckun F.M.; Venkatachalam T.; Preparation of AZT derivatives exhibiting spermicidal and anti-viral activity. 2002"},{"key":"ref=83","author":"Wang T.","year":"2004","unstructured":"Wang T.; Zhang Z.; Meanwell N.A.; Kadow J.F.; Yin Z.; Xue Q.M.; Regueiro-Ren A.; Matiskella J.D.; Ueda Y.; Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives. 2004"},{"key":"ref=84","author":"Son J. C.","year":"1995","unstructured":"Son J. C.; Lee I. Y.; Bae B. I.; Han J. S.; Choi J. K.; Chae Y. B.; Novel antiviral 2,4-pyrimidinedione derivatives and processes for the preparation thereof. 1995"},{"key":"ref=85","author":"Gavegnano C.","year":"2019","unstructured":"Gavegnano C.; Schinazi R.F.; Antiviral pyrrolo[2,3-b]pyridine and pyrrolo[2,3-b]pyrimidine JAK inhibitors useful in treating or preventing retroviral and other viral infections. 2019"},{"key":"ref=86","author":"Zhang H.","year":"2014","unstructured":"Zhang H.; Pan T.; Luo H.; Zhang X.; Bai C.; Application of 1- (2-chlorophenyl)-4-{thieno [3,2-d]pyrimidin-4-yl} piperazine compound in preparing anti-HIV-1 drugs. 2014"},{"key":"ref=87","author":"Fan X.","year":"2013","unstructured":"Fan X.; Zhang X.; Li X.; Wang Y.; Xu H.; Guo S.; He Y.; 5- Substituted pyrimidine nucleoside-thiazolinone hybrid compound with anti-HIV activity and preparation method. 2013"},{"key":"ref=88","author":"Wang Q.","year":"2013","unstructured":"Wang Q.; Wang C.; Li Y.; Tan J.; Wang M.; Yao X.; Qiao W.; Geng Y.; Liu Y.; Wang Li.; Preparation of pyrimidineamide derivatives with anti-HIV and anti-TMV activity. 2013"},{"key":"ref=89","author":"Chaltin P.","year":"2011","unstructured":"Chaltin P.; Debyser Z.; De Maeyer M.; Marchand A.; Marchand D.; Smets W.; Voet A.; Christ Fr.; Pyrimidine derivatives as novel viral replication inhibitors and their preparation and use in the treatment of HIV infection. 2011"},{"key":"ref=90","author":"Wang T.","year":"2003","unstructured":"Wang T.; Zhang Z.; Meanwell Ni.; Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives. 2003"},{"key":"ref=91","author":"Pedersen E.B.","year":"2003","unstructured":"Pedersen E.B.; Jorgensen P.; Preparation of anti-retroviral 5,6- disubstituted acyclo-pyrimidine nucleoside derivatives 2003"},{"key":"ref=92","author":"Lori F.","year":"2011","unstructured":"Lori F.; De Forni D.; Stevens M.R.; Anti-proliferative substituted pyrazolo[3,4-d]pyrimidines derivatives (SPP) to inhibit immune activation, virus replication and tumor growth 2011"},{"key":"ref=93","author":"Cho U. H.","year":"2007","unstructured":"Cho U. H.; Jung S. G.; Myung H. N.; Kwon H. S.; Lee S. H.; Lee J. U.; Ju J.; Antiviral pyrimidinedione derivatives. 2007"},{"key":"ref=94","author":"Zemlicka J.","year":"2002","unstructured":"Zemlicka J.; Qiu Y.-l.; Drach J. C.; Ptak R. G.; Preparation of 2- hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents. 2002"},{"key":"ref=95","author":"Tets V. V.","year":"2016","unstructured":"Tets V. V.; Tets G. V.; Krasnov K. A.; Drug preparation with antiviral activity (versions). 2016"},{"key":"ref=96","author":"Chu C. K.","year":"2003","unstructured":"Chu C. K.; Otto M. J.; Shi J.; Schinazi R.F.; Choi Y.; Gumina G.; Preparation, antiviral activity, and cytotoxicity of \u03b2-2'- and 3'- halo-nucleosides. 2003"},{"key":"ref=97","author":"Kim J.W.","year":"1997","unstructured":"Kim J.W.; Chung K.H.; Ahn S.K.; Son H.J.; Jeong B.S.; Preparation of nucleosides as anti-hepatitis-B virucides 1997"},{"key":"ref=98","author":"Guo X.","year":"2019","unstructured":"Guo X.; Tao Y.; Li Y.; Dong L.; Liu L.; Wang Q.; Yu X.; 4-amino acid substituted pyrimidine nucleoside compound and application thereof in preparing antiviral myocarditis drugs and anticoxsackie virus drugs. 2019"},{"key":"ref=99","author":"Lancois D. F. A.","year":"2016","unstructured":"Lancois D. F. A.; Guillemont J. E. G.; Raboisson P. J.-M. B.; Roymans D. A. E.; Rogovoy B.; Bichko V.; Lardeau D. Y. R.; Michaut A. B.; Preparation of pyrazolo- and triazolo-pyrimidine compounds as RSV antiviral agents. 2016"},{"key":"ref=100","author":"Tahri A.","year":"2016","unstructured":"Tahri A.; Vendeville S.M.H.; Jonckers T.H.M.; Raboisson P.J.-M.B.; Demin S.D.; Hu L.; Preparation of piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives as respiratory syncytial virus inhibitors 2016"},{"key":"ref=101","author":"Tahri A.","year":"2016","unstructured":"Tahri A.; Vendeville S. M. H.; Jonckers T. H. M.; Raboisson P. J.-M. B.; Demin S. D.; Hu L.; Cooymans L. P.; Preparation of piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives as respiratory syncytial virus inhibitors. 2016"},{"key":"ref=102","author":"Wutzler P.","year":"2013","unstructured":"Wutzler P.; Schmidtke M.; Makarov V.; Process for production of 4-amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidines. 2013"},{"key":"ref=103","author":"Yoshimura Y.","year":"1997","unstructured":"Yoshimura Y.; Sato H.; Matsuda A.; Ashida N.; Machida H.; Preparation of 2'-deoxy-2'-methylidene-4'-thiopyrimidine nucleosides as antiviral agents. 1997"},{"key":"ref=104","author":"Townsend L. B.","year":"1995","unstructured":"Townsend L. B.; Drach J. C.; Renau T. E.; Pyrrolo[2,3-d]pyrimidine derivatives as antivirals. 1995"},{"key":"ref=105","author":"Ashkinazi R. I.","year":"2001","unstructured":"Ashkinazi R. I.; Ganina M. B.; Studentsov E. P.; Bioactive substance containing derivatives of 2-amino-6-(aryloxy)pyrimidines and intermediate products of their synthesis. 2001"},{"key":"ref=106","author":"Herdewijn P.","year":"2001","unstructured":"Herdewijn P.; Wang J.; De Clercq E.; Preparation of carbocyclic nucleosides as antiviral agents. 2001"},{"key":"ref=107","author":"Tets V.V.","year":"2005","unstructured":"Tets V.V.; Tets G.V.; Krutikov V.I.; Preparation of 2,4-dioxo-5-(2-hydroxy-3,5-dichlorobenzylidene)imino-1,3-pyrimidine sodium, potassium and ammonium salts having antimicrobial activity. 2005"},{"key":"ref=108","author":"Hertel L.W.","year":"1993","unstructured":"Hertel L.W.; Kroin J.S.; 2'-deoxy-2',2'-difluoro-(4-substituted pyrimidine) nucleosides having antiviral and anti-cancer activity and intermediates. 1993"},{"key":"ref=109","author":"Townsend L. B.","year":"1990","unstructured":"Townsend L. B.; Drach J. G.; Shipman C.; Pudlo J. S.; Preparation of acyclic pyrrolo(2,3-d)pyrimidine nucleoside analogs as antiviral agents. 1990"},{"key":"ref=110","year":"1987","unstructured":"Antiviral and antitumor-enhancing activities of pyrimidin-2-ones. 1987"},{"key":"ref=111","author":"Bardos T. J.","year":"1984","unstructured":"Bardos T. J.; Cheng Y. C.; Schroeder A. C.; Inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nucleosides. 1984"},{"key":"ref=112","author":"Shealy Y.","year":"1983","unstructured":"Shealy Y.; Carbocyclic analogs of uracil nucleosides as antiviral agents. 1983"},{"key":"ref=113","author":"Townsend L.B.","year":"2002","unstructured":"Townsend L.B.; Drach J.C.; Preparation of pyrrolo[2,3-d]pyrimidines as antiviral agents 2002"},{"key":"ref=114","author":"Balzarini J.","year":"2009","unstructured":"Balzarini J.; Camarasa M. J.; Velazquez S.; Improvements in or relating to compositions for the treatment or prophylaxis of viral infections, especially varicella zoster virus, by using nucleoside analogs esterified at 3 and\/or 5 positions by neutral non-polar amino acid, or oligopeptide. 2009"},{"key":"ref=115","first-page":"1004","volume":"1","author":"Asraf M.A.","year":"2020","unstructured":"Asraf M.A.; Hossen M.F.; Bitu N.A.; Uddin M.E.; Islam M.R.; Zamir R.; Zahan M.K.; Antiviral Compounds: A Road to Quest for Novel Antiviral Drugs Ann Med Chem 2020,1(1),1004","journal-title":"Ann Med Chem"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.2174\/1389557520666200729160720","volume":"20","author":"Kushwaha N.","year":"2021","unstructured":"Kushwaha N.; Sharma C.S.; The Chemistry of Triazine Isomers: Structures, Reactions, Synthesis and Applications. Mini Rev Med Chem 2021,20(20),2104-2122","journal-title":"Mini Rev Med Chem"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijid.2020.02.018","volume":"93","author":"Andersen P.I.","year":"2020","unstructured":"Andersen P.I.; Ianevski A.; Lysvand H.; Vitkauskiene A.; Oksenych V.; Bj\u00f8r\u00e5s M.; Telling K.; Lutsar I.; Dumpis U.; Irie Y.; Tenson T.; Kantele A.; Kainov D.E.; Discovery and development of safe-in-man broad-spectrum antiviral agents. Int J Infect Dis 2020,93,268-276","journal-title":"Int J Infect Dis"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1002\/hep.22900","volume":"49","author":"Ghany M.G.","year":"2009","unstructured":"Ghany M.G.; Doo E.C.; Antiviral resistance and hepatitis B therapy. Hepatology 2009,49(S5),S174-S184","journal-title":"Hepatology"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1478-3231.2010.02399.x","volume":"31","author":"Zoulim F.","year":"2011","unstructured":"Zoulim F.; Hepatitis B virus resistance to antiviral drugs: where are we going?  Liver Int 2011,31(1(S1)),111-116","journal-title":"Liver Int"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1039\/c9pp00211a","volume":"18","author":"Wiehe A.","year":"2019","unstructured":"Wiehe A.; O\u2019Brien J.M.; Senge M.O.; Trends and targets in antiviral phototherapy. Photochem Photobiol Sci 2019,18(11),2565-2612","journal-title":"Photochem Photobiol Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"ofw223.","DOI":"10.1093\/ofid\/ofw223","volume":"3","author":"Ewers E.C.","year":"2016","unstructured":"Ewers E.C.; Shah P.A.; Carmichael M.G.; Ferguson T.M.; In Concurrent systemic chemo immunotherapy and sofosbuvir-based antiviral treatment in a hepatitis C virus-infected patient with diffuse large B-cell lymphoma. Open Forum Infect Dis 2016,3(4),ofw223.","journal-title":"Open Forum Infect Dis"},{"key":"ref=121b","first-page":"S237","volume":"36","author":"Fried M.W.","year":"2002","unstructured":"Fried M.W.; Side effects of therapy of hepatitis C and their management. Hepatology 2002,36(5)(Suppl. 1),S237-S244","journal-title":"Hepatology"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2217\/fmb.15.82","volume":"10","author":"Hanson K.E.","year":"2015","unstructured":"Hanson K.E.; Swaminathan S.; Cytomegalovirus antiviral drug resistance: future prospects for prevention, detection and management. Future Microbiol 2015,10(10),1545-1548","journal-title":"Future Microbiol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jama.2014.8897","volume":"312","author":"Brennan T.","year":"2014","unstructured":"Brennan T.; Shrank W.; New expensive treatments for hepatitis C infection. JAMA 2014,312(6),593-594","journal-title":"JAMA"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijid.2020.03.004","volume":"94","author":"Wu D.","year":"2020","unstructured":"Wu D.; Wu T.; Liu Q.; Yang Z.; The SARS-CoV-2 outbreak: What we know. Int J Infect Dis 2020,94,44-48","journal-title":"Int J Infect Dis"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/jmv.25701","volume":"92","author":"Li X.","year":"2020","unstructured":"Li X.; Wang W.; Zhao X.; Zai J.; Zhao Q.; Li Y.; Chaillon A.; Transmission dynamics and evolutionary history of 2019-nCoV. J Med Virol 2020,92(5),501-511","journal-title":"J Med Virol"},{"key":"ref=126","author":"Koszytkowska-Stawinska M.","year":"2013","unstructured":"Koszytkowska-Stawinska M.; Process for the preparation of new phosphono-substituted azanucleosides. 2013"},{"key":"ref=127","author":"Cornaglia F. P.","year":"1992","unstructured":"Cornaglia F. P.; Stradi R.; Preparation of pyrimidine derivatives with pharmacological activities. 1992"},{"key":"ref=128","author":"Zhang S.","year":"2009","unstructured":"Zhang S.; Xiong G.; Antiviral composition of (R)-9-[2- (phosphorylmethoxy)propyl]adenine and (2R,cis)-4-amino-1-(2- hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one. 2009"},{"key":"ref=129","author":"Balzarini J.","year":"2009","unstructured":"Balzarini J.; Camarasa M.J.; Velazquez S.;  Improvements in or relating to compositions for the treatment or prophylaxis of viral infections, especially varicella zoster virus, by using nucleoside analogs esterified at 3 and\/or 5 positions by neutral non-polar amino acid, or oligopeptide. 2009"},{"key":"ref=130","author":"Cho D. G.","year":"2002","unstructured":"Cho D. G.; Cho U. Y.; Choi J. R.; Hwang J. T.; Jang H. S.; Kim E. G.; Kim J. M.; Lee J. H.; Lim J. H.; Noh G. Y.; Preparation of antiviral 2,4-pyrimidinedione derivatives. 2002"},{"key":"ref=131","author":"Sonn J. C.","year":"1998","unstructured":"Sonn J. C.; Lee I. Y.; Bae B. I.; Han J. S.; Choe J. K.; Chae Y. B.; A novel process for the preparation of antiviral 2,4- pyrimidinedione derivatives. 1998"},{"key":"ref=132","author":"Loebering H. G.","year":"1982","unstructured":"Loebering H. G.; Miestereck H.; Pyrimidine nucleosides esterified in position 5' having antiviral activity and medicinal compositions containing them. 1982"},{"key":"ref=133","author":"Keppeler K.","year":"1982","unstructured":"Keppeler K.; Kiefer G.; Substituted pyrimidine nucleosides with an antiviral activity and drug forms prepared with them. 1982"},{"key":"ref=134","author":"Kiefer G.","year":"1982","unstructured":"Kiefer G.; Keppeler K.; Substituted pyrimidine nucleosides with antiviral and cytostatic activity. 1982"},{"key":"ref=135","author":"Grinev A.N.","year":"1980","unstructured":"Grinev A.N.; Kharizomenova I.A.; Panisheva E.K.; Tolstikova E.V.; Bogdanova N.S.; Nikolaeva I.S.; Peters V.V.; Pershin G.N.; Derivatives of 3-(p-benzoquinonylimino)-4-oxo-3,4- dihydrothieno[2,3-d]pyrimidine with antivirus activity. 1980"},{"key":"ref=136","author":"Slusarchyk W. A.","year":"1992","unstructured":"Slusarchyk W. A.; Zahler R.; Preparation of an optically active [bis(hydroxymethyl)cyclobutyl]pyrimidine derivative as an antiviral agent. 1992"},{"key":"ref=137","author":"Kaplina N. V.","year":"1993","unstructured":"Kaplina N. V.; Shvedov V. I.; Fomina A. N.; Nikolaeva I. S.; Pushkina T. V.; Filitis L. N.; Thieno-[2,3-d]pyrimidines having herpes virus inhibitory and antituberculosis activities. 1993"},{"key":"ref=138","author":"Ichikawa Y.","year":"1990","unstructured":"Ichikawa Y.; Ishikawa F.; Matsuo K.; Aoyama K.; Nishiyama Y.; Matsubara K.; Nagahata T.; Hoshino H.; Seki J.;  Preparation of 1-[3-(hydroxymethyl)cyclobutyl]pyrimidine derivatives as virucides. 1990"},{"key":"ref=139","author":"Marquez V.E.","year":"1989","unstructured":"Marquez V.E.; Driscoll J.S.; Preparation of cyclopentenylpyrimidine and -purine derivatives as antiviral and antitumor agents. 1989"},{"key":"ref=140","author":"Takaku H.","year":"1988","unstructured":"Takaku H.; Yoshida S.; Aoki T.; Akiba K.; Preparation of acyclic nucleosides cyclic phosphoramidates having antiviral and anticancer activities. 1988"},{"key":"ref=141","author":"Holy A.","year":"1988","unstructured":"Holy A.; Rosenberg I.; De Clercq E.; Preparation and testing of N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases with antiviral activity 1988"},{"key":"ref=142","author":"Gatti D.","year":"1984","unstructured":"Gatti D.; Pyrimidine derivatives endowed with antiviral activity. 1984"},{"key":"ref=143","author":"Jiang C.","year":"2005","unstructured":"Jiang C.; He H.; Xu L.; Lin G.; Preparation of anti-virus nucleoside analogs. 2005"},{"key":"ref=144","author":"Miyasaka T.","year":"1989","unstructured":"Miyasaka T.; Tanaka H.; De Clercq E.D.A.; Baba M.; Walker R.T.; Ubasawa M.;  6-substituted acyclic pyrimidine nucleoside derivatives and antiviral agents containing same as active ingredients. 1989"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"e18063","DOI":"10.1590\/s2175-97902019000118063","volume":"55","author":"Chiamenti L.","year":"2019","unstructured":"Chiamenti L.; Silva F.P.; Schallemberger K.; Demoliner M.; Rigotto C.; Fleck J.D.; Cytotoxicity and antiviral activity evaluation of Cymbopogon spp hydroethanolic extracts. Braz J Pharm Sci 2019,55,e18063","journal-title":"Braz J Pharm Sci"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557523666221220142911","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/212062\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557523666221220142911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T14:28:23Z","timestamp":1692455303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/212062\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":146,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557523666221220142911","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}